728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

Ossen Innovation Announces Voting Results of the Special Meeting of Shareholders

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

SHANGHAI, Jan. 18, 2018 /PRNewswire/ — Ossen Innovation Co., Ltd. (the “Company”) (Nasdaq: OSN), a China-based manufacturer of an array of plain surface, rare earth and zinc coated pre-stressed steel materials, is pleased to announce the final voting results for the proposal considered at the Company’s special meeting that was held on January 17, 2018 (the “Meeting”). At the Meeting, the Company’s shareholders approved the amended terms of the Company’s proposed acquisition of American-Asia Diabetes Research Foundation.

A total of 17,570,262 ordinary shares, representing approximately 88.8% of the Company’s issued and outstanding ordinary shares, were represented at the Meeting. Dr. Tang abstained from voting all of the 11,850,000 shares he holds, as previously disclosed by the Company.

The final voting results for the proposal to approve a share exchange agreement and related transactions providing for the acquisition by the Company of 100% of the outstanding capital stock of American-Asia Diabetes Research Foundation, a California corporation, in exchange for 81,243,000 of the Company’s ordinary shares were as follows:

For

Against

Abstain

5,650,515

69,747

11,850,000

The ordinary shares voted in favor of the proposal submitted at the Meeting include both (i) a majority of all of the issued and outstanding ordinary shares of the Company as of the record date other than the shares held by Dr. Tang and (ii) a majority of all of the issued and outstanding ordinary shares of the Company as of the record date other than shares held by Dr. Tang, Fascinating Acme Development Limited and Gross Inspiration Development Limited. Each of Fascinating Acme Development Limited and Gross Inspiration Development Limited may be deemed to be an affiliate of the Company and each holds 600,000 ordinary shares of the Company.

The closing of the transaction, as well as the closing of the sale of the Company’s current business to Dr. Tang, which transaction was previously approved by the Company’s shareholders, is conditioned upon the approval of the initial listing application of America-Asia Diabetes Research Foundation by Nasdaq.

About America-Asia Diabetes Research Foundation

America-Asia Diabetes Research Foundation is a California corporation which conducts its business through its subsidiary, San MediTech (Huzhou) Co., Ltd. San MediTech, based in Huzhou City, China, engages in the research, development and marketing of glucose control products. San MediTech’s proprietary DGMS provides continuous,

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *